Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Brain Neoplasms 1

Interventions

Radiosurgery 11Temozolomide 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Nivolumab 4Mental Status and Dementia Tests 4Receptors, Interleukin-8B 3Memantine 3Ipilimumab 3trastuzumab deruxtecan 2pembrolizumab 2Surveys and Questionnaires 2sotorasib 1sapanisertib 1sacituzumab govitecan 1pertuzumab 1patritumab deruxtecan 1nabiximols 1fluciclovine F-18 1entrectinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1brodalumab 1auricularum 1abemaciclib 1Watchful Waiting 1Vorinostat 1Vitamin B 6 1Valacyclovir 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Diffusion Tensor Imaging × 30 days × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡